Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Paul M. Barr, Jennifer Brown, Peter Hillmen, Susan O’Brien, Jacqueline C. Barrientos, Nishitha Reddy, Steven Coutré, Stephen P. Mulligan, Ulrich Jaeger, Richard R. Furman,

Blood · 2017 · 143 citations · 10 references

DOIFull text

Open access

Concepts

Abstract

status. Of 79 patients requiring a drug hold, treatment was restarted at the original dose in 73 (92%) patients. Mean duration of a missed-dose event was 18.7 days (range, 8-56). Patients missing ≥8 consecutive days of ibrutinib had a shorter median PFS vs those missing <8 days (10.9 months vs not reached). These results support sustained adherence to once-daily ibrutinib dosing at 420 mg as clinically feasible to achieve optimal outcomes in patients with previously treated CLL. The trial was registered at www.clinicaltrials.gov as #NCT01578707.

References

10